Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript February 28, 2024 Mirum Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.33. MIRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]
We sat down with Jessica Ferrell, PhD, to discuss key takeaways from her session about the developing role of bile acids both for and beyond cholestatic and metabolic diseases.
A trio of investigators discuss how research into bile acid interplay with the gut may lead to breakthroughs in treating conditions like NAFLD and NASH.